secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2026-05-15T20:29:39+00:00
Accession:  0001213900-26-057828
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M
-------------------------------------------------------------

- Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
- Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.
- Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.
- MENA segment sales surged 446%, partially offsetting U.S. decline.
- Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/0001213900-26-057828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/ea0290896-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-057828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer